Market Closed -
Nasdaq
16:00:00 2024-05-31 EDT
5-day change
1st Jan Change
0.437
USD
+9.25%
+4.05%
-80.05%
Aethlon Medical, Inc. Announces Board Changes, Effective as of October 30, 2020
November 03, 2020 at 08:01 am
Aethlon Medical, Inc. announced that Mr. Ed Broenniman replaced Dr. Fisher as the Chairman of the Board effective as of October 30, 2020.
Top Midday Decliners
05-15
MT
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
05-13
MT
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday
05-13
MT
Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma
05-10
CI
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
02-14
CI
Transcript : Aethlon Medical, Inc., Q3 2024 Earnings Call, Feb 14, 2024
02-14
Transcript : Aethlon Medical, Inc., Q2 2024 Earnings Call, Nov 14, 2023
11-14
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
11-14
CI
Aethlon Medical, Inc Announces Executive Changes
11-13
CI
Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer
11-13
CI
HC Wainwright Adjusts Price Target on Aethlon Medical to $23 From $90, Maintains Buy Rating
23-10-24
MT
Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology
23-10-10
CI
Aethlon Medical Board Approves 1-for-10 Reverse Stock Split
23-10-04
MT
Transcript : Aethlon Medical, Inc., Q1 2024 Earnings Call, Aug 10, 2023
23-08-10
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
23-08-10
CI
Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee
23-07-06
CI
Transcript : Aethlon Medical, Inc., Q4 2023 Earnings Call, Jun 28, 2023
23-06-28
Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
23-06-28
CI
Transcript : Aethlon Medical, Inc., Q3 2023 Earnings Call, Feb 13, 2023
23-02-13
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
23-02-13
CI
Aethlon Medical Taps Namsa to Manage Planned Clinical Trial of Medical Device for Cancer
23-01-30
MT
North American Morning Briefing : Stock Futures -2-
22-11-16
DJ
Maxim Downgrades Aethlon Medical to Hold From Buy
22-11-15
MT
Transcript : Aethlon Medical, Inc., Q2 2023 Earnings Call, Nov 14, 2022
22-11-14
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
22-11-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
More about the company
Last Close Price
0.437
USD
Average target price
10
USD
Spread / Average Target
+2,188.33%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
AETHLON MEDICAL, INC. 
